R Squared Ltd Reduces Stock Position in Encompass Health Corporation $EHC

R Squared Ltd trimmed its position in shares of Encompass Health Corporation (NYSE:EHC) by 68.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,821 shares of the company’s stock after selling 5,993 shares during the period. R Squared Ltd’s holdings in Encompass Health were worth $273,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. WPG Advisers LLC lifted its holdings in shares of Encompass Health by 73.3% during the fourth quarter. WPG Advisers LLC now owns 324 shares of the company’s stock valued at $34,000 after purchasing an additional 137 shares during the last quarter. Flagship Harbor Advisors LLC bought a new stake in Encompass Health in the 4th quarter valued at $37,000. Caitong International Asset Management Co. Ltd increased its position in Encompass Health by 36,200.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock worth $46,000 after purchasing an additional 362 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Encompass Health in the fourth quarter worth $55,000. Finally, Covestor Ltd boosted its holdings in Encompass Health by 24.4% during the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock valued at $57,000 after acquiring an additional 106 shares during the period. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Stock Performance

Shares of EHC opened at $110.17 on Thursday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99. The business’s fifty day moving average price is $103.56 and its 200 day moving average price is $103.43. The stock has a market capitalization of $10.93 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 2.41 and a beta of 0.74.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, April 30th. The company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the business earned $1.37 EPS. The firm’s revenue was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities research analysts forecast that Encompass Health Corporation will post 5.97 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is 12.69%.

Analyst Ratings Changes

Several analysts have commented on EHC shares. Weiss Ratings lowered shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, June 26th. Leerink Partners set a $152.00 target price on Encompass Health in a research report on Friday, May 22nd. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. TD Cowen assumed coverage on shares of Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 price target on the stock. Finally, Barclays decreased their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $143.86.

Insider Activity at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the sale, the executive vice president directly owned 24,755 shares of the company’s stock, valued at $2,588,382.80. The trade was a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.80% of the stock is currently owned by corporate insiders.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.